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Background/aim: Congenital heart disease (CHD) is a common birth defect. Many studies have reported GATA4 mutations in patients
with CHD, mainly septal defects. This study aimed to investigate the GATA4 exon 1 mutation in Egyptian patients with isolated
congenital heart defects as a possible causative mutation.
Materials and methods: Screening for mutations or any sequence variations in exon 1 of the GATA4 gene was carried out by PCR
amplification followed by direct sequencings in 165 Egyptian patients with different nonsyndromic congenital heart diseases and 93
controls who were matched in terms of age and sex. Thorough clinical assessments were done for all subjects, along with X-ray, 2D
echocardiography, and Doppler examinations.
Results: The most common CHD among our cases was isolated ventricular septal defect (VSD) in 47.3% (78/165), followed by isolated
atrial septal defect. A novel nonsynonymous sequence variation in fragment 2 (P193H) of exon 1 of GATA4 was detected in 15 (9.1%)
of the subjects with septal defects. This mutation was not seen in any of the control group subjects.
Conclusion: There is a high prevalence of exon 1 GATA4 mutation (9.1%) in our study compared to other studies in different populations,
which may correlate with different ethnic populations.
Key words: Congenital heart disease, cardiac septal defects, GATA4 mutation

1. Introduction
Congenital heart diseases (CHDs) are the most widely
recognized noninfectious cause of mortality in the
neonatal period. The incidence of CHD ranges from 19
to 75/1000 (1–3). However, almost 15% of patients with
CHD have been distinguished as having single gene or
chromosomal defects, which are considered as a part of
syndromes or environmental factors, while the rest of the
patients (85%) show multifactorial inheritance (4).
GATA4, which maps to chromosome 8p23, is a main
transcription factor that regulates different physiological
processes and has an important role in heart development
(5,6). Numerous heterozygous mutations have been
distinguished in previous mutation screenings of GATA4
(MIM: 600576) with sporadic or familial CHD (2,5,7). Not
much is known about the common mutations in patients
with CHD in Egypt. In the present study we investigated the
possible causative mutation in Egyptian patients with CHDs.
* Correspondence: nogaota5000@yahoo.com

2. Subjects and methods
2.1. Subjects
This case control study enrolled 165 patients (81 males and
84 females) and 93 controls (51 males and 42 females).
They were all Egyptian and recruited between May 2013
and October 2014 from the outpatient cardiac clinic or the
Pediatric Cardiology Department of Abu-Elreish Hospital
with echocardiographic evidence of CHD. Patients with
any dysmorphic features, 22q deletion, Down syndrome,
or any other numerical or structure chromosomal
abnormality were excluded. The controls were matched
to the patients in terms of age and sex. The cases were
classified according to the type of CHD into isolated (VSD,
ASD, PDA, PS, TOF, AP window) or combined (VSD with
ASD/ASD with PDA).
The research protocol was approved by ethical
committee of Kasr al Ainy hospital. Written informed
consent was obtained from the parents of each patient
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prior to enrollment in the study. Following enrollment,
a detailed medical history was obtained, and a clinical
assessment and physical examination for malformation
and dysmorphology were done with exclusion of any
affected or suspected syndromes. A family pedigree
was constructed for each subject, and a high resolution
chromosomal study showed that all subjects had a normal
karyotype. FISH microdeletion studies for our suspected
cases of DiGeorge spectrum were done with exclusion
of positive cases. All our patients and controls had chest
X-ray study, 2D echocardiography was used to detect
cardiac septal defects, and the direction of the shunt color
flow mapping was obtained. Doppler examinations were
done to assess the pulmonary blood flow. The images were
obtained according to the usual standardization (8). Some
patients underwent cardiac catheterization. A pediatric
cardiologist diagnosed and classified CHD.
2.2. Methods
2.2.1. Genetic testing for GATA4 sequence variations
DNA was extracted from peripheral blood leukocyte
samples using the QIAamp DNA minikit (Qiagen, USA)
following the manufacturer’s instructions. DNA samples
were subjected to DNA quantitation and purity assessment
using the NanoDrop (ND)-1000 spectrophotometer
(NanoDrop Technologies, Inc. Wilmington, DE, USA).
The amplified PCR products of fragment 1 were shown
at 422 bp (Figure 1). All DNA samples were screened
for mutations or any sequence variations in exon 1 of
the GATA4 gene. Screening was carried out by PCR
amplification of exon 1 using two overlapping primers
followed by direct sequencings (9). Cycle sequencing PCR
was carried out on a PerkinElmer thermal cycler (Applied
Biosystem 2720, Singapore) (Table 1).

2.2.2. PCR amplification of exon 1
The reaction mixtures were made in a total volume of 50
µL containing 0.5 µg of genomic DNA, 10X buffer, 0.25
mM dNTPs, 2.5 pmol of each primer (MWG-Biotech,
Germany), and 2 units of Taq polymerase. PCR was
carried out using the following conditions: denaturation at
94 °C for 10 min, followed by 30 cycles of denaturation at
93 °C for 50 s, annealing at 60 °C for 50 s, and elongation
at 72 °C for 50 s, followed by a final extension at 72 °C
for 5 min. The PCR products were analyzed for successful
amplification on 2% agarose gel electrophoresis stained
with ethidium bromide.
Purification of the PCR products was performed using
the QIAquick PCR purification kit (Qiagen, Germany).
According to this kit protocol 5 volumes of Buffer PB
were added to 1 volume of the PCR product and mixed
well. The samples were then applied to the QIAquick
column and centrifuged for 1 min at 10,000 rpm. The
washing step was carried out using 0.75 mL of Buffer
PE followed by centrifugation at 10,000 rpm for 1 min.
PCR products were then eluted in 30 µL of sterile H2O
followed by spinning the column at 10,000 rpm for 1
min. Cycle sequence PCR was carried out using a BigDye
Terminator kit (Applied Biosystems, Foster City, CA,
USA). To prepare the reaction mixtures, the following
components were mixed: 8.0 µL of the terminator-ready
reaction mix, 10–30 ng of PCR products, and 3.2 pmol of
primer (forward or reverse primer), and then sterile H2O
was added to reach a 20 µL final reaction volume. Cyclesequencing PCR was carried out with a PerkinElmer
thermal cycler (Applied Biosystems 2720, Singapore)
using the following conditions: denaturation at 96 °C for 1
min, followed by 25 cycles of denaturation at 96 °C for 10
s, annealing at 58 °C for 5 s, and elongation at 60 °C for 4
min. CENTRI-SEP purification spin columns were used to

Figure 1. The amplified PCR products of fragment 1 were shown at 422 bp.

Table 1. PCR primers for exon 1 GATA4.
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Primer

Sequence

Fragment 1

F:5’- TGTTGCCGTCGTTTTCTCTC -3’
R:5’- GTCCCCGGGAAGGAGAAG-3’

Fragment 2

F:5’- CGACGGAGCCGCTTACAC -3’
R:5’- CGACGGAGCCGCTTACAC -3’
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remove dye terminators before applying the sample to the
sequencer (Applied Biosystems, Foster City, CA, USA).
This purification provides excellent recovery of DNA
fragments and removes >98% of salts, dNTPs, and other
low-molecular-weight compounds. The samples were
injected into an automatic sequencer and the data were
analyzed using the ABI Prism DNA sequencing analysis
software.
3. Results
3.1. Patients
The 165 CHD patients (81 males and 84 females) were
children (age range 1 month–16 years). The controls were
healthy children matched to the patients in terms of age
and sex with no family history of CHD.
The most common CHD among our cases was isolated
ventricular septal defect (VSD) (47.3%, 78/165), followed
by isolated atrial septal defect (ASD) (16.4%, 27/165),
combined VSD and ASD (14.6%, 24/165), tetralogy
of Fallot (TOF) (7.3%, 12/165), and 24 (15.4%) other
abnormalities (Table 2).
3.2. Consanguinity
Positive consanguinity has been elicited in 48/165 cases
(29%). Five of the patients with sequence variation showed
positive consanguinity (4/15, 26.6%).
3.3. GATA4 nonsynonymous sequence variation
No sequence variations were identified in fragment 1
PCR amplification of exon 1 of the GATA4 gene. While
a nonsynonymous sequence variation in fragment 2 was
detected in 15/165 (9.1), all of them had cardiac septal
defect 15/129 (11.6%) including 9 of 78 with isolated VSD
(11.5%) and 6 of 24 with combined VSD and ASD (25%).
This variant conferring a base substitution (A) instead
of (C) (578C > A) resulting in amino acid change from

proline (CCC) to histidine (CAC) at codon 193 (P193H)
(Figure 2). This mutation was not found in the control
group.
4. Discussion
The most common nonsyndromic CHDs are ASD, VSD,
and TOF, which are reported in about 60% of all CHDs
(4). The GATA4 gene is a zinc finger protein belonging to
an evolutionarily conserved GATA family that consists of
six members.
It is located on chromosome 8p23, and is one of the
key transcription factors that is involved at all stages in the
regulatory pathways of heart development (4,5,9–11).
Over 20 heterozygous mutations in the GATA4 gene
have been described in previous publications mainly
in cases of ASD, VSD, atrio-ventricular septal defects,
pulmonary stenosis (PS), and TOF (2,5,12,13).
In this study, we detected a novel single-base nucleotide
substitution (578C > A) that altered a single amino acid
(P193H) in the GATA4 gene. This heterozygous missense
mutation was detected in 15 of 165 (9.1%) of our patients.
The high frequency of our results is consistent with the
10% GATA4 mutation found in a previous study done by
Chen et al. (14). However, this high prevalence is different
from the 2.1% (8/384) and 2.5% (12/486) in 2 studies
done by Zhang et al. and Wang et al. in sporadic Chinese
CHD patients (5,7). Our prevalence is also higher when
compared to the 0.8% (5/628) GATA4 mutation detected
in American patients in a study done by Tomita-Mitchell
et al. (9). All the previous mentioned studies examined
larger panels of cases compared to ours.
Positive consanguinity was determined in 48/165
cases (29%). Four of the patients with sequence variation
showed positive consanguinity (4/15, 26.6%). However,
consanguinity has no role in this situation, as all detected

Table 2. Phenotypes of the patients with congenital heart disease.
Cardiac defect

Patients (165)

%

VSD

78

47.3

ASD

27

16.4

VSD, ASD

24

14.6

TOF

12

7.3

PARTIAL AV CANAL

6

3.6

COMPLETE AV CANAL

6

3.6

PS

6

3.6

ASD, PDA

3

1.8

AP WINDOW

3

1.8
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Figure 2. Sequencing analysis of fragment 2 in a patient with P193H mutation (II) in comparison with a control case
(I). The figure shows a portion of the sequencing electropherogram of fragment 2. The second base of codon 193 was
substituted (A) instead of (C) leading to its change from proline (CCC) to histidine (CAC).

mutation showed heterozygous defect (autosomal
dominant mode) (MIM: 600576) (4,5,7,12,15).
Our study population was composed of small numbers
for each type of cardiac malformation. However, this
cannot rule out the likelihood that mutations in GATA4
have a higher frequency in certain sporadic cases of CHD
such as ASD, VSD, TOF, or pulmonary stenosis.
In this study, we had a diversity of lesions including
78 (47.3%) cases of VSD, 27 (16.4%) ASD, 24 (14.6%)
combined VSD and ASD, 12 TOF (7.3%), and 24 (15.4%)
other abnormalities. Similar diversity of lesions was found
in the study by Zhang et al. (10) that included 24 cases of
VSD (39%), 14 cases of ASD (23%), 7 cases of TOF (11%),
3 cases of PS (5%), and 2 cases of AV canal defect (3%)
and other lesions. Similar diversity of lesions was found in
other studies done by Butler et al. and Tomita-Mitchell et
al. (9,12). The study was limited to VSD cases only in the
study by Wu et al. (16) and septal defects as in the study
done by Chen et al. (14).
The nonsynonymous sequence variation in exon 1 of
GATA4 (P193H) was detected in cases of septal defects:
isolated VSD and combined VSD and ASD. Another
study revealed 4 missense mutations in 4 out of 300
nonsyndromic patients (1.3%); all of them had VSD with

220

other minor anomalies, two mutations in exon 1 of GATA4
(G69D and P163R) in addition to 2 mutations in 3 cases in
exon 6 (A411V and D425N) (13), while in the study done
by Tomita Mitchell et al. four mutations were identified in
5 patients, 4 of them with septal defect and one with TOF
(G93A, Q316E, A411V, D425N); they were distributed in
exon 1 and exon 4 and 2 mutations in 2 cases in exon 6
(9). Chen et al. did not detect any mutation in exon 1 but
there was mutation in 5 cases in exon 2 and 7. Moreover,
the study done by Hussein et al. (17) showed no mutation
in exon 1 but it showed 1 mutation in 2 cases in exon 6.
One of the most important outcomes in our study was
the presence of a high frequency of mutations in exon 1
of GATA4 (9.1%) compared with other studies in different
populations. However, most of them shared the fact that
they mainly had cardiac septal defects. The different
CHD cases in different ethnic groups, however, may be
the result of several factors, such as epigenetic regulation,
genetic background (different races), modifier genes
and environmental factors, and even the personalized
genetic signature (4,5,15,16). This finding highlights the
importance of studying GATA4 sequence variation on a
large scale in Egyptian children with CHD.
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